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Schizophrenia (SZ) is an inheritable complex mental disease. There have been several genome-wide association studies (GWASs) 
of SZ to identify novel genetic susceptibility factors. To further interpret SZ GWASs, pathway-based analysis (PBA), which con-
siders the combined effect of variants and identifies pathways associated with traits, provides a feasible solution to discover the 
biological function and mechanism of SZ. Furthermore, to investigate the common pathways between SZ and bipolar disorder 
(BD) will help explore common mechanism between psychiatric phenotypes. We performed a PBA, called improved gene set 
enrichment analysis (i-GSEA), on 3 independent GWASs of SZ to identify pathways associated with SZ. The results were further 
compared to the BD-associated pathways identified by i-GSEA for 2 BD GWASs and from literature reports. Our analysis identi-
fied a highly statistically significant association between SZ and pathway ‘substrate specific channel activity’ in all 3 SZ GWASs 
(false discovery rate (FDR) < 0.05). This association has not been reported elsewhere before. This pathway was also identified by 
PBA for 2 independent BD GWASs. Our results suggest that pathway ‘substrate specific channel activity’ is statistically signifi-
cantly associated with SZ, and SZ and BD share the common biological function and mechanism represented by this pathway.  
schizophrenia (SZ), genome-wide association study (GWAS), pathway-based analysis (PBA), bipolar disorder (BD) 
 
Citation:  Zhang K L, Zhang L Y, Zhang W N, et al. Pathway-based analysis for genome-wide association studies of schizophrenia to provide new insight in 




Schizophrenia (SZ) is a complex mental disease, character-
ized by hallucinations, delusions and cognitive deficits and 
caused by both genetic and environmental factors and their 
interactions. SZ has a global lifetime prevalence about 
0.4%–1% [1,2], with heritability estimated at approximately 
80%–85% [3]. However, the susceptibility genes or biolog-
ical mechanisms for SZ are still not well-known.  
Genome-wide association study (GWAS), which utilizes 
genome-wide single nucleotide polymorphism (SNP) array 
to identify genetic susceptibility through detecting the asso-
ciation between genotype frequency and trait [4], provides 
an opportunity to detect the effects of common variants with 
greater power than linkage analysis. According to the col-
lection of GWAS Catalog (www.genome.gov/gwastudies) 
[5], there have been 10 SZ GWASs till 2010, which were 
mainly based on European ancestry population. However, 
the first 6 SZ GWASs did not find any genome-wide sig-
nificant or meaningful variant which is expected to have the 
potential association with SZ [6–11]. The reasons are prob-
ably these studies have been performed using pooled DNA, 
ethnically heterogeneous samples or small samples sizes 
(there is no study including more than 1000 cases), which 
reduced the power of GWAS to detect the effects of com-
mon SNPs. After increasing the sample size and improving 
the experimental design and analytical strategy, the SGENE 
consortium, the International Schizophrenia Consortium 
(ISC) and the Molecular Genetics of Schizophrenia consor-
tium (MGS) found several genome-wide significant SNPs 
in the major histocompatibility complex (MHC) region on 
chromosome 6 [12–14]. Besides this, several significant 
variants also indicate the association between SZ and the 
genes involved in brain development, memory and cogni-
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tion. However, these GWAS analyses focused on single 
SNP/gene and identified only a number of the most signifi-
cant SNPs, which accounted for a small proportion of the 
genetic variants, so they offered limited understanding of 
schizophrenia. Thus, the method for detecting the combined 
genetic effect of SZ is expected to be applied to SZ GWASs 
for further GWAS data interpretation and mechanism study 
of SZ.  
Pathway-based analysis (PBA) which was originally de-
veloped for analyzing gene expression data [15] has been 
introduced to GWAS data analysis to detect the association 
between pathway and trait [16–18]. It has been proved to be 
a feasible solution to interpret GWAS result and to promote 
the analytical level from SNP/gene to pathway. An im-
portant PBA approach is the gene set enrichment analysis 
(GSEA) which technically evaluates whether the genes 
sharing a biological function is enriched at the top of a 
ranked genome-wide gene list [16]. In our previous work, 
we designed and implemented a novel PBA method, called 
i-GSEA (improved gene set enrichment analysis). i-GSEA 
employs the analytical framework of GSEA while it em-
phasizes on identifying the pathways containing high pro-
portion of significant genes. Our study has shown that 
i-GSEA is a powerful PBA approach to detect the dis-
ease-related pathways reflecting the combined genetic effect 
of complex disease with high sensitivity [19]. To perform 
PBA (i.e. i-GSEA) on SZ GWASs will help discover path-
ways associated with SZ to provide new insight in SZ study. 
In addition, since SZ is assumed to share some common 
genetic factors with bipolar disorder (BD) [20], applying 
PBA on BD GWASs to investigate the pathways associated 
with both SZ and BD will help explore common mechanism 
between psychiatric phenotypes (SZ and BD).  
In this study, we performed the PBA (i-GSEA) on 3 in-
dependent SZ GWASs, and then we investigated these 
pathways by comparing them with the BD-associated path-
ways identified by PBA (i-GSEA) for 2 BD GWASs and 
from 7 PBA reports from literatures. We identified that 
pathway ‘substrate specific channel activity’ is associated 
with SZ with highly statistical significance (false discovery 
rate (FDR) < 0.05 in all 3 SZ GWASs). This pathway was 
also detected by PBA for 2 independent BD GWASs.  
1  Materials and methods  
1.1  Materials  
We requested and obtained 2 SZ GWAS SNP P-value da-
tasets, namely Genetic Association Information Network 
(GAIN) European ancestry (GAIN_EA, Accession No. 
pha002857.v1.p1) and GAIN African American ancestry 
(GAIN_AA, Accession No. pha002859.v1.p1), from  
dbGaP (http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap). 
Data access was approved by the GAIN DAC. The third SZ 
GWAS SNP P-value data set from Duke Study European 
ancestry (DS_EA) samples were obtained directly from ref. 
[11]. These 3 datasets are the only data that allow public 
access and none of them have identified SNP(s) with ge-
nome-wide significance. In the same way, we requested and 
obtained 2 BD GWAS data, namely GAIN European ances-
try (GAIN_EA, Accession No. pha002858.v1.p1) and 
GAIN African American ancestry (GAIN_AA, Accession 
No. pha002863.v1.p1), from dbGaP. The details of the 3 
GWAS datasets of SZ and 2 GWAS datasets of BD are 
shown in Table 1.  
Pathway dataset, which serves as the search space of our 
PBA, consists of pathways from BioCarta (http://www.  
biocarta.com/), KEGG [21], and gene ontology (GO) [22] 
biological process domain and molecular function domain 
(we used curated GO terms from MSigDB [23] plus level 4 
GO terms). In order to avoid over large or over small search 
space and functional category, only the pathways with size 
(number of genes involved) more than 20 and less than 200 
were used in our PBA analysis.  
Other PBA results of BD, which were used for a com-
prehensive comparison between our PBA results of SZ and 
BD-associated pathways, were collected from refs. [19, 
24–32], as detailed in Table 2.  
1.2  Methods  
To analyze the 3 GWAS datasets for SZ and the 2 GWAS 
datasets for BD, for each dataset, we firstly retrieved SNP 
and gene localizations on human chromosomes from the 
Ensembl database [33]. Then we associated each SNP with 
its nearest gene with distance less than 500 kb [16]. Second,   
Table 1  The detailed information of different GWASs of SZ and BDa)  
GWAS dataset (disease name) Ethnicity Number of cases/controls Number of genotyped SNPs 
GAIN_EA (SZ) European ancestry 1351/1378 over 729454 
GAIN_AA (SZ) African American ancestry 1195/954 over 845814 
DS_EA (SZ) European ancestry 900/877 over 312565 
GAIN_EA (BD) European ancestry 1001/1034 over 728222 
GAIN_AA (BD) African American ancestry 362/671 over 845814 
a) GAIN_EA, Genetic Association Information Network European ancestry; GAIN_AA, Genetic Association Information Network African American 
ancestry; DS_EA (SZ), Duke Study European ancestry for SZ (ref. [11]).  
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Table 2  Summary of the available PBA results for BD GWASsa) 
GWAS dataset PBA approach Major finding Reference 
WTCCC   i-GSEA  glutathione metabolism  [19] 
WTCCC  hypergeometric test  heparan sulfate, Niacin-HDL metabolism, adrenergic receptor- 
mediated cytoskeletal remodeling pathways  
[24] 
WTCCC  Prioritizing Risk Pathways fusing 
SNPs and pathways (PRP)  
purine metabolism, phosphatidylinositol signaling system, MAPK 
signaling pathway, p53 signaling pathway, arachidonic acid me-
tabolism, WNT signaling pathway, etc  
[25] 
WTCCC  hypergeometric test (Fisher’s exact 
test), Sidak’s method, Simes’ 
method, Simes/FDR method  
Inositol metabolism, Glycine, serine and threonine metabolism, 
N-Glycan biosynthesis, Chondroitin sulfate biosynthesis, Fatty 
acid metabolism, Nucleotide sugars metabolism, Chondroitin 
sulfate biosynthesis, Heparan sulfate biosynthesis, etc  
[26] 
WTCCC  SNP ratio test  cell adhesion molecule (CAM)  [27] 
WTCCC + NIMH    Fisher exact test  ion channel activity, synaptic neurotransmission  [28] 
WTCCC + STEP-UCL +  
ED-DUB-STEP2   
ALIGATOR (Association LIst Go 
AnnoTatOR)  
transcription and cellular activity, including that which occurs via 
hormonal action  
[29] 
a) WTCCC, Wellcome Trust Case Control Consortium (ref. [30]); NIMH, National Institutes of Mental Health (ref. [31]); STEP-UCL, Systematic 
Treatment Enhancement Program for Bipolar Disorder-University College London; ED-DUB-STEP2, University of Edinburgh-Trinity College Dublin- 
Systematic Treatment Enhancement Program for Bipolar Disorder additional (ref. [32]).  
 
 
the PBA, i.e. i-GSEA as reported in our recent study [19], 
was applied to the SNP P-values of the 3 SZ GWASs re-
spectively, by using the pathway datasets described above 
as search space. The key running procedures of i-GSEA are 
as follows: (1) The lowest P-value of the SNPs of a gene is 
utilized to represent the gene. (2) For each pathway, en-
richment score (ES, a Kolmogorov-Smirnov like statistics 
with weight 1), which reflects the trend that genes of the 
pathway held better associations than genome-wide genes, 
is calculated based on ranked gene list. (3) A significant 
proportion ratio, which emphasizes the relative proportion 
of significant genes (defined as genes mapped with at least 
1 SNP with P-value < 0.05), is multiplied to ES to obtain 
significance proportion based ES (SPES). (4) SNP label 
permutation and normalization are performed to generate 
the null distribution of SPES and correct gene variation and 
gene set variation. Let u be permutation and S be pathway. 
For a specific permutation u* and a specific pathway S*, 
SPES(u*,S*) is computed by repeating (1)–(3). Normalized 
SPES(S*) (i.e. NSPES(S*)) equals to (SPES(S*)–m)/sd, 
where m is the mean of SPES(u,S*) and sd is the standard 
deviation of SPES(u,S*). NSPES(u*,S*) is calculated by us-
ing the same way as NSPES(S*). (5) Nominal P-value is 
calculated and false discovery rate (FDR) is used for multi-
ple testing correction [34]. For a specific pathway S*, nom-
inal P-value = (number of NSPES(u,S*) which are greater 
than or equal to NSPES(S*))/(number of NSPES(u,S*)). 
FDR = (percentage of NSPES(u,S) which are greater than or 
equal to NSPES(S*))/(percentage of NSPES(S) which are 
greater or equal to NSPES(S*)). We kept those pathways 
with FDR < 0.05 as candidate pathways associated with SZ. 
Figure 1 shows the key procedures of i-GSEA. Finally, we 
compared the i-GSEA results of SZ with BD-associated 
pathways (our i-GSEA results of BD and other PBA results 
from literatures) to study the common function and mecha-
nism between SZ and BD. 
 
Figure 1  Key procedures of i-GSEA.  
2  Results  
2.1  Overview of the results  
In PBA for SZ GAIN_EA data, 674868 SNPs were mapped 
to 17198 genes, 980 pathways were selected, and 36 path-
ways with FDR < 0.05; in PBA for SZ GAIN_AA data, 
782587 SNPs were mapped to 17440 genes, 991 pathways 
were selected, and 5 pathways with FDR < 0.05; in PBA for 
SZ DS_EA data, 288615 SNPs were mapped to 16697 genes, 
972 pathways were selected, and 19 pathways with FDR < 
0.05. Our analysis identified the highly statistically signifi-
cant (FDR < 0.05) association between schizophrenia and 
pathway ‘substrate specific channel activity’ in all 3 GWASs 
(FDR = 0.034, 0.047, and 0.016 in GAIN_EA, GAIN_AA, 
and DS_EA respectively). Immunity-related pathways with 
highly statistical significance were also identified in all the 3 
GWASs of SZ by our PBA analysis. Since they have been 
well reported before, we will not elaborate it in this paper.  
In PBA for BD GAIN_EA data, 673770 SNPs were 
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mapped to 17186 genes, 981 pathways were selected and 60 
pathways with FDR < 0.05; in PBA for BD GAIN_AA data, 
782587 SNPs were mapped to 17440 genes, 991 pathways 
were selected and 3 pathways with FDR < 0.05. There is no 
pathway with FDR < 0.05 in both GWASs.  
Comparison between SZ-associated pathway ‘substrate 
specific channel activity’ by PBA and BD-associated path-
ways show that pathway ‘substrate specific channel activity’ 
is shared by both SZ and BD, which indicate the possible 
common function and mechanism between the 2 diseases.  
2.2  Pathway ‘substrate specific channel activity’ 
The pathway ‘substrate specific channel activity’ (GO Ac-
cession: GO: 0022838) is defined as energy-independent 
facilitated diffusion catalysis that is mediated by passage of 
a specific solute through a channel or transmembrane 
aqueous pore. This pathway consists of 3 sub-pathways (or 
called child nodes of GO tree), namely ‘ion channel activi-
ty’ (GO: 0005216), ‘urea channel activity’ (GO: 0015265), 
and ‘water channel activity’ (GO: 0015250). The pathway 
‘substrate specific channel activity’ describes a specific 
kind of channel activity, which covers ion channel activity. 
It is well known that ion channels play extremely important 
roles in potential based neuron function, so the abnormality 
of this activity may be a possible risk factor of SZ.  
The pathway ‘substrate specific channel activity’ is also 
presented in our result of PBA for BD GWAS (FDR = 
0.042, for BD GWAS of GAIN_EA) and its sub-pathway 
‘ion channel activity’ is presented in the result of PBA for 
BD GWAS performed by Askland et al. [28], which ana-
lyzed the Wellcome Trust Case Control Consortium 
(WTCCC) data [30] and National Institutes of Mental 
Health (NIMH) data [31] (Bonferroni-adjusted P-value = 
0.0064 in WTCCC and Bonferroni-adjusted P-value = 
0.0035 in NIMH, respectively). Thus, the pathway ‘sub-
strate specific channel activity’ was identified by 2 PBA 
analyses corresponding to 2 independent GWASs of BD.  
The significant PBA result of SZ and its shared common 
pathway with BD are shown in Table 3.  
3  Discussion  
As the GWASs for SZ identified only a few number of 
SNPs/genes and offer limited understanding of the disease, 
PBA is important to further interpret SZ GWASs to detect 
functional units associated with SZ. In our PBA for differ-
ent SZ GWASs, the pathway ‘substrate specific channel 
activity’ was identified. Pathway ‘substrate specific channel 
activity’ was not presented in single SNP/gene based analy-
sis and its association with SZ was first reported by us. This 
shows that our analysis has the power of interpreting the 
GWASs of SZ to further identify disease-related mechanism 
and provide new insight into the study of SZ. It should be 
noted that the PBA approach, i-GSEA, does not take into 
account the linkage disequilibrium (LD) of SNPs, since LD 
can only be analyzed when genotype data is available (for 
most published GWAS investigations, genotype data is usu-
ally not available). It assumes that all the input SNPs are 
independent (i.e. there is no LD between them) while per-
forming permutation. This may lead to some bias as SNPs 
tend to be non-independent. So for GWAS with genotype 
data available, to input SNPs not in LD (say r2<0.2) is rec-
ommended to reduce the possibility of biased results.  
The pathway ‘substrate specific channel activity’ found 
in this report is statistically replicable and across ethnic 
groups because it’s presented in 3 PBA results for 3 inde-
pendent SZ GWASs (including 2 GWASs for European 
ancestry population and 1 GWAS for African American 
ancestry population). Recently, a PBA analysis, which 
combined GSEA and Fisher exact test, for 1 single SZ 
GWAS (GAIN_EA) has found that the metabolism of glu-
tamate, the process of apoptosis, inflammation, and immune 
system could be associated with SZ [35]. The other PBA 
analysis of SZ, which utilized SNP ratio test, for 2 SZ 
GWASs, namely GAIN_EA and ISC (International Schiz-
ophrenia Consortium), identified that pathway ‘cell adhe-
sion molecule (CAM)’ (an immune-related pathway) is as-
sociated with SZ [27]. This research has also found that 
CAM is also associated with BD (by analyzing WTCCC 
BD GWAS [30]). There are 2 reasons may lead to the dif-
ferent results between these 2 researches and our research. 
One is that the above 2 researches only focused on the pop-
ulation with European ancestry while our work focused   
on populations both with European ancestry and African 
ancestry. The other reason is that different researches uti-
lized different methods of PBA with different parameters. 
Our result has been proved to be solid because it is statisti-
cally significant in all 3 independent SZ GWASs corre- 
sponding to 2 different ethnic groups. Apparently for the 
same trait, different ethnic groups should share the same  
Table 3  The significant result of pathway ‘substrate-specific channel activity’ in PBA analyses for SZ and BD GWASs 
GWAS dataset (disease name) PBA approach P-value FDR 
GAIN_EA (SZ) i-GSEA < 0.001 0.034 
GAIN_AA (SZ) i-GSEA < 0.001 0.047 
DS_EA (SZ) i-GSEA < 0.001 0.016 
GAIN_EA (BD) i-GSEA < 0.001 0.042 
WTCCC + NIMH (BD) Fisher exact test 1.27E-5a) (in WTCCC) 6.99E-6a) (in NIMH) 0.0064b) (in WTCCC) 0.0035b) (in NIMH) 
a) For ‘ion channel activity’, the sub-pathway of ‘substrate-specific channel activity’; b) Bonferroni-adjusted P-value for sub-pathway ‘ion channel activity’. 
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biological functions and mechanisms. 
It is the first time that the association between pathway 
‘substrate specific channel activity’ and SZ is identified, 
and the association is statistically significant and outstand-
ingly solid. It has been known that SZ and BD share some 
common genetic factors [12]. Our study further indicates 
that they share some common biological mechanism, ‘sub-
strate specific channel activity’, and it is not found by the 
single SNP/gene based analysis of GWAS. This novel result 
provides the new evidence for the shared biological mecha-
nisms between SZ and BD.  
4  Conclusions  
Our results suggest that the pathway ‘substrate specific 
channel activity’ is associated with SZ, and SZ and BD 
share this common biological function and mechanism.  
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